

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# **FOSUN PHARMA**

## **复星医药**

**上海復星醫藥（集團）股份有限公司**

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 02196)**

### **(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR AND (2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board hereby announces the resignation of non-executive Director and proposed appointment of executive Director as follows:

- (1) Mr. Wu Yifang resigned as a non-executive Director due to personal work reassignment with effect from 30 September 2025; and
- (2) It is proposed that Mr. Liu Yi be appointed as an executive Director of the tenth session of the Board.

#### **CIRCULAR**

A circular containing, among others, further details regarding the proposed appointment of Mr. Liu Yi as an executive Director and a notice of the general meeting will be dispatched to the Shareholders in due course.

#### **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

On 30 September 2025, the board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) received the resignation letter from Mr. Wu Yifang (吳以芳) (“**Mr. Wu**”). Mr. Wu resigned as a non-executive Director due to personal work reassignment. In accordance with the articles of association of the Company, the resignation of Mr. Wu from the above-mentioned position shall become effective from 30 September 2025.

Mr. Wu has confirmed that there is no disagreement between him and the Board and/or the Company during his term of office and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”).

The Company hereby expresses its sincere gratitude to Mr. Wu for his valuable contribution during his term of office.

## **PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board is pleased to announce the proposed appointment of Mr. Liu Yi (劉毅) (“**Mr. Liu**”) as an executive Director of the tenth session of the Board. The appointment of Mr. Liu is subject to the approval of the Shareholders at the general meeting. The biographical details of Mr. Liu are set out as follows:

Mr. Liu, aged 50, is currently the Company’s chief executive officer and president, the chairman and chief executive officer of the MedTech division\* (診療科技事業部), and holds directorships and management positions in certain subsidiaries of the Company, including serving as an executive director and the chairman of the board of directors of Sisram Medical Ltd (stock code: 01696), a company listed on the Hong Kong Stock Exchange, and a non-executive director of Shanghai Henlius Biotech, Inc. (stock code: 02696), a company listed on the Hong Kong Stock Exchange.

Mr. Liu joined the Group in November 2015 and served as the chief technology officer of the medical devices division and in other positions of the Company. He was a vice president of the Company from January 2017 to January 2022 and a senior vice president of the Company from January 2022 to June 2025, and has been the chief executive officer and president of the Company since June 2025. Prior to joining the Group, Mr. Liu was mainly engaged in the field of medical devices and medical diagnostics. Mr. Liu obtained a bachelor’s degree in engineering from Beijing Institute of Technology, a master’s degree in management from Peking University and a doctorate degree in biomedical engineering from Beihang University.

As at the date of this announcement, Mr. Liu has not entered into a service contract as an executive Director with the Company. Mr. Liu will not receive any remuneration from the Company for his appointment as an executive Director, and the relevant director’s service contract will not provide for a specific remuneration amount. The proposed appointment of Mr. Liu as an executive Director of the tenth session of the Board will be effective upon the approval of the Shareholders at the general meeting and end on the expiration of the term of the tenth session of the Board.

Mr. Liu has confirmed that, save as disclosed above, as at the date of this announcement, he does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company, and does not hold any other positions in the Company or any of its subsidiaries nor any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years. As at the date of this announcement, within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong

Kong) (the “SFO”), Mr. Liu has personal interests in 35,444 shares of the Company (including 15,444 A shares and 20,000 H shares), representing approximately 0.001% of the total number of shares of the Company. Save as disclosed above, Mr. Liu does not have any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Hong Kong Listing Rules, nor any other matters relating to the proposed appointment of Mr. Liu as an executive Director that need to be brought to the attention of the Shareholders.

## **CIRCULAR**

A circular containing, among others, further details regarding the proposed appointment of Mr. Liu as an executive Director and a notice of the general meeting will be dispatched to the Shareholders in due course.

By order of the Board  
**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***  
**Chen Yuqing**  
*Chairman*

Shanghai, the PRC  
30 September 2025

*As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee Director of the Company is Ms. Yan Jia.*

\* For identification purposes only